Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Spigel

Showing results (151-160 of 211) with videos related to

Pageof 22
Sort By:
Clinical Lung Cancer|October 24, 2020
Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical TrialDavid R Spigel, Robert M Jotte, Santiago Ponce Aix, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 28, 2017
Current and Emergent Therapy Options for Advanced Squamous Cell Lung CancerMark A Socinski, Coleman Obasaju, David Gandara, et al.
Journal for Immunotherapy of Cancer|March 14, 2024
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trialHeinz-Josef Lenz, Aparna Parikh, David R Spigel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 31, 2016
Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of TreatmentCorey J Langer, Coleman Obasaju, Paul Bunn, et al.
The Lancet. Oncology|August 2, 2021
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket studyMilind Javle, Mitesh J Borad, Nilofer S Azad, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 1, 2026
Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC TrialSuresh Senan, Byoung Chul Cho, Konstantin K Laktionov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III TrialKaren Kelly, Nasser K Altorki, Wilfried E E Eberhardt, et al.
Melanoma Research|November 25, 2020
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)F Stephen Hodi, Paul B Chapman, Mario Sznol, et al.
The New England Journal of Medicine|September 30, 2020
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLCRoy S Herbst, Giuseppe Giaccone, Filippo de Marinis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2022
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2Dwight H Owen, Navneet Singh, Nofisat Ismaila, et al.
Pageof 22

Showing results (151-160 of 211) with videos related to

Sort By:
Pageof 22
Clinical Lung Cancer|October 24, 2020
Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical TrialDavid R Spigel, Robert M Jotte, Santiago Ponce Aix, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 28, 2017
Current and Emergent Therapy Options for Advanced Squamous Cell Lung CancerMark A Socinski, Coleman Obasaju, David Gandara, et al.
Journal for Immunotherapy of Cancer|March 14, 2024
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trialHeinz-Josef Lenz, Aparna Parikh, David R Spigel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 31, 2016
Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of TreatmentCorey J Langer, Coleman Obasaju, Paul Bunn, et al.
The Lancet. Oncology|August 2, 2021
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket studyMilind Javle, Mitesh J Borad, Nilofer S Azad, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 1, 2026
Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC TrialSuresh Senan, Byoung Chul Cho, Konstantin K Laktionov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III TrialKaren Kelly, Nasser K Altorki, Wilfried E E Eberhardt, et al.
Melanoma Research|November 25, 2020
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)F Stephen Hodi, Paul B Chapman, Mario Sznol, et al.
The New England Journal of Medicine|September 30, 2020
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLCRoy S Herbst, Giuseppe Giaccone, Filippo de Marinis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2022
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2Dwight H Owen, Navneet Singh, Nofisat Ismaila, et al.
Pageof 22